超肥満患者における経カテーテル大動脈弁留置術:高リスク表現型の定義
Abdul Rasheed Bahar1, Waqas Ullah2, Yasemin Bahar1
1Detroit Medical Center/ Wayne State University, Detroit, MI, USA.
Background:
The long-term impact of super obesity (body mass index [BMI] ≥50 kg/m²) on outcomes after transcatheter aortic valve implantation (TAVI) is not well defined.
Methods:
We used the 2015-2020 Nationwide Readmissions Database to identify TAVI procedures and compared patients with super obesity to those with BMI <50 kg/m². Propensity score-matched cohorts were constructed using clinical covariates. We evaluated net adverse cardiovascular events (NACE; composite of in-hospital mortality, stroke, and major bleeding), mortality, and complications during index admission and at 30 and 180 days. A prespecified subgroup analysis compared super-obese with normal-BMI patients.
Results:
Among 184,199 TAVI procedures, 4,669 patients (2,369 super obese, 2,300 non-super obese) were included in the matched cohort. Super-obese TAVI volume increased over time. At index admission, super-obesity was associated with higher odds of NACE (adjusted odds ratio [aOR] 1.57, 95% CI 1.12-2.20), in-hospital mortality (aOR 8.08, 95% CI 3.19-20.48), and acute kidney injury (aOR 1.48, 95% CI 1.25-1.74), whereas stroke and major bleeding did not differ. At 30 days, only acute kidney injury remained higher in super-obese patients, and by 180 days only permanent pacemaker implantation was increased (aOR 2.55, 95% CI 1.34-4.85).In subgroup analyses restricted to super-obese versus normal-BMI patients, super-obesity was associated with higher NACE and complications at index admission and 180 days.
Conclusions:
Super-obese TAVI recipients have higher early risk and persistent excess risk for selected complications, indicating that extreme obesity defines a higher-risk TAVI phenotype despite broadly comparable longer-term outcomes versus patients with lower BMI.
さらに関連する動画
関連する概念動画
Drug Dosing: Obese Patients
Atherosclerosis III: Management
Obesity
Aortic Regurgitation III: Medical Management
Mitral Valve Prolapse II: Assessment and Management
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution


